Medical device company IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported higher revenues and net income for the fourth quarter of 2024.
- Fourth-quarter revenues increased 6% annually to $954.3 million; organic revenue growth was 6%
- Net income attributable to shareholders moved up to $216.1 million in Q4 from $194.5 million a year earlier
- On a per-share basis, fourth-quarter earnings rose to $2.62 from $2.32 in Q4 2023
- For fiscal 2025, the management expects revenues to be in the range of $4.06 billion to $4.17 billion, reflecting a growth of 4-7%
- Full-year organic revenue growth is expected to be between 6% and 9%
- The management is looking for earnings of $11.74 per share to $12.24 per share for FY25, an increase of 10-15% on a reported basis
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Infographic: Amazon (AMZN) Q4 2024 earnings beat estimates; sales rise 10%
E-commerce giant Amazon.com Inc. (NASDAQ: AMZN) on Thursday reported higher sales and profit for the fourth quarter of 2024. Earnings also beat analysts' estimates. Net sales increased to $187.8 billion
Philip Morris (PM) delivers strong performance in 4Q24 helped by smoke-free strength
Shares of Philip Morris International Inc. (NYSE: PM) jumped 10% on Thursday after the company delivered better-than-expected earnings results for the fourth quarter of 2024 and provided an encouraging outlook
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in revenue. Net income attributable to shareholders was $72 million or